Company

About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.

History

2015

  • Dec Hanmi launches oral wound rinse ‘MuGard’ for cancer patients
  • 3rd-generation EGFR TKI, HM61713(Olmutinib), receives FDA Breakthrough Therapy Designation in lung cancer
  • Spectrum Announces Agreement with FDA on the Special Protocol Assessment(SPA) for the Registrational Trial of eflapegrastim, a Novel, Long Acting G-CSF in Patients with Breast Cancer
  • Nov Hanmi and Sanofi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
  • Hanmi and ZAI Lab execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China
  • Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug(IND) Application for Poziotinib
  • Hanmi launches new dual-action hyperlipidemia drug 'Rosuzet'
  • Hanmi Signs an Exclusive License Agreement with Janssen Pharmaceuticals, Inc. to Develop a Novel Biologic for Treatment of Diabetes and Obesity
  • OctHanmi set new record in sales in Q3
  • Hanmi Enters Agreement with Serenus Bio to Bring Combination Therapy to Fight off Hypertension in Africa
  • SepHanmi presented the results of Efeglenatide's Phase IIb clinical trial at 2015 EASD
  • AugHanmi Enters Research Collaboration for a Next Generation Biologic Drug with a Bio-Venture
  • JunHanmi to Present 3rd-generation EGFR TKI, HM61713 at 2015 ASCO
  • Hanmi to Present its New Diabetes Drugs Including Quantum Project at 2015 ADA Scientific Sessions
  • AprHanmi to Build “Global Smart Facility” for Export of Finished Products
  • MarLicensed out ‘Poziotinib’ (targeted anticancer agent) to Spectrum Pharma in US
  • Beginning US Phase Ⅲ clinical trial for its osteoarthritis medicine Hyalrheuma
  • Licensed out immunological therapy ‘HM71224’ to Eli lilly (Deal size : 780 bil won)
  • Started phase 2 clinical trial of new antibody target lung cancer drug, HM61713
  • Presented a new long-acting human growth hormone drug (LAPSrhGH) at the endocrine society conference
  • FebInitiated phase I clinical trial of first in class weekly insulin in US
  • Targeted anti-cancer agents Poziotinib, goes on phase 2 to expand indications for Breast cancer
  • JanCP Grade impoved from BBB to A
  • Participated in JP Morgan healthcare conference
  • $20 million strategic investment with Allegro Ophthalmics(ophthalmic Bioventure)
  • Initiated phase I clinical trial of first in class weekly insulin in US
  • 35th Blood Drive...a total of 4,883 people participated
  • Co promotion agreement of ‘Godex’ with Celltrion